Last reviewed · How we verify
NCT04913532
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
NA trial testing Hypofractionation with simultaneous integrated boost in Breast Cancer in 35 participants. Completed in 31 July 2025.
30 June 2023
Quick facts
| Lead sponsor | Capital Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 22 June 2021 |
| Primary completion | 30 June 2023 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Hypofractionation with simultaneous integrated boost
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Surgery — all drugs for Surgery →
- Adjuvant Radiotherapy — all drugs for Adjuvant Radiotherapy →
Sponsor
Capital Medical University
Who can join
18 and older, female only, with Breast Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. However, Hypofractionation with simultaneous integrated boost has been investigating in breast cancer. Investigators initiated this phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy.
Arenas M, Bölükbaşı Y, Boersma LJ, Offersen B, et al · · 2025 · cited 2× · PMID 39854807 · DOI 10.1016/j.breast.2025.103881
Verify or expand the search:
- PubMed search for NCT04913532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Capital Medical University trials
Trials by the same sponsor.
- NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
- NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04913532 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
- Last refreshed: 23 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04913532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing